William Hait - 21 Apr 2022 Form 4 Insider Report for JOHNSON & JOHNSON (JNJ)

Role
Officer
Signature
Raavi Deol, as attorney-in-fact for William Hait
Issuer symbol
JNJ
Transactions as of
21 Apr 2022
Net transactions value
-$2,766,076
Form type
4
Filing time
25 Apr 2022, 16:33:28 UTC
Previous filing
18 Feb 2022
Next filing
26 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNJ Common Stock Options Exercise $2,685,978 +29,699 +37% $90.44 109,935 21 Apr 2022 Direct
transaction JNJ Common Stock Sale $18,358 -100 -0.09% $183.58 109,835 21 Apr 2022 Direct F1
transaction JNJ Common Stock Sale $18,358 -100 -0.09% $183.58 109,735 21 Apr 2022 Direct F1
transaction JNJ Common Stock Sale $41,305 -225 -0.21% $183.58 109,510 21 Apr 2022 Direct F1
transaction JNJ Common Stock Sale $128,504 -700 -0.64% $183.58 108,810 21 Apr 2022 Direct F1
transaction JNJ Common Stock Sale $257,559 -1,403 -1.3% $183.58 107,407 21 Apr 2022 Direct F1
transaction JNJ Common Stock Sale $311,347 -1,696 -1.6% $183.58 105,711 21 Apr 2022 Direct F1
transaction JNJ Common Stock Sale $529,436 -2,884 -2.7% $183.58 102,827 21 Apr 2022 Direct F1
transaction JNJ Common Stock Sale $4,147,188 -22,591 -22% $183.58 80,236 21 Apr 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JNJ Employee Stock Options (Right to Buy) Options Exercise $0 -29,699 -50% $0.000000 29,698 21 Apr 2022 Common Stock 29,699 $90.44 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from 183.57 to 183.64. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

Title: Executive Vice President, Chief External Innovation, Medical Safety and Global Public Health Officer